Fig. 1: Validation of HERV-K measurements of a clinical trial data.
From: Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia
A Phylogeny of Retroviridae family with HERV-K and HERV-W belong to different genera (italicized) (adapted from Weiss et al. 24). B ddPCR amplification of the HERV-K and HERV-W env gene with forward primer (red), reverse primer (green) and probe (blue). C Validation of the antiretroviral drug Triumeq effect on HERV-K levels before and after 24 weeks of treatment in ALS patients (n = 9). Data represent individual patients, mean and SE as error bars. D HERV-W levels before and after 24 weeks of treatment with Triumeq in ALS patients (n = 9). Data represent individual patients, mean and SE as error bars. E A comparison of HERV-K and HERV-W env levels in control (n = 21), FTD (n = 63) and ALS (n = 89) serum. Data represent median with min and max as whiskers. *P < 0.05, **P < 0.001, ***P < 0.0001.
